eligibility_summary
Adults (≥21) with self-reported RMS, SPMS, or CIS who can complete English questionnaires. OCR cohort: currently on Ocrevus with ≥1 year on therapy, exclude those in MS drug trials or whose last Ocrevus infusion was <3 months ago. OMB cohort: currently on ofatumumab (OMB) with ≥6 months on therapy, exclude those in MS drug trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Non-interventional study assessing “wearing‑off” symptoms in MS patients on anti‑CD20 therapies. Drugs: ocrelizumab (Ocrevus)—humanized IgG1 monoclonal antibody, IV every 6 months, ofatumumab (Kesimpta)—fully human IgG1 monoclonal antibody, monthly subcutaneous. Mechanism of action: both bind CD20 on pre‑B and mature B lymphocytes, inducing B‑cell depletion via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis, sparing plasma cells. Targets: CD20+ B cells, pathways include B‑cell antigen presentation, cytokine signaling, and T‑cell costimulation in MS.